Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG INNOLET.
HUMALOG MIX 75/25 vs NOVOLOG INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Category C
Category C
Insulin Analog
Insulin Analog